---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-076938"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:17:24.230049+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee

## Summary
- Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
- Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.
- Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.
- TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.
- Company cites unavailable capital markets as reason to seek a strategic partner.

## SEC filing metadata
- accession: 0001193125-25-076938
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/0001193125-25-076938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/d906762d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-076938
- JSON: https://secwatch.observer/filing/0001193125-25-076938.json
- Plain text: https://secwatch.observer/filing/0001193125-25-076938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.